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Research Article    
Abstract 
Atherosclerosis is a systemic disease that occurs due to the formation of Fibro-fatty lesions in 
arteries that block blood flow. The process of Atherosclerosis is initiated through mechanical, 
chemical, and immunological activation of the endothelium. Even there are microorganisms 
involved in the different stages of atherosclerosis. There are a number of molecular factors, RNA's, 
macrophages, and enzymes that play a vital role in the progression and development of 
Atherosclerosis that alter the metabolism of Fibro-fatty. Receptors of micro RNA proliferate and 
regulate endothelial activation and smooth cell Macrophages, monocytes, t-cell, and natural 
killer cells are involved in the boosting of the immune system to prevent atherosclerotic lesion 
formation. In this review, we can know how RNA's involved in the pathophysiology side of 
atherosclerosis and explore the mechanism to regulate Atherosclerosis, and how macrophages 
evoke an immune response. Therefore, the use of synthetic and natural drugs and following the 
right diet timely prevent and reduce the risk of development of Atherosclerosis.  
 
Keywords: Atherosclerosis, Fibro-fatty, RNA, Cardiac vascular disease 
 
1. Introduction 
Cardiac vascular disease (CVD) is one of the leading diseases that affect the whole world. CVD 
includes Ischemic heart disease, Myocardial-infarction, and Atherosclerosis. CVD is the leading 
cause of death in India, when compared with a western population only 23% of people below 
the age of 70 are affected by CVD whereas in India above 52% of people are affected due to 
an imbalanced diet, use of Tobacco, alcohol intake and smoking.  
Atherosclerosis is the vital cause of death in industrialized societies, soon to be worldwide. 
Atherosclerosis is a systemic disease that affects elderly people. It is the hardening and narrowing 
of arteries.  Arteries are responsible for the flow of oxygen-rich blood from the heart to the entire 
body at a young age but as we grow older our arteries become narrow and harden and there is 
a formation of fibro-fatty lesions in arteries that may block the flow of blood. It changes the 
accumulation of lipids, calcium, blood components, carbohydrates, and fibrous tissue on the 
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Figure 1 - The atherosclerosis-plaque develops in the coronary arteries 
(Prasad G Jamkhande-2014) 
 
The recent update found that the intracellular bacterial pathogen Chlamydia pneumoniae 
causes respiratory tract infection and has been associated with atherosclerosis and coronary 
artery disease. C. pneumoniae is involved in all stages of atherosclerosis including initiation, 
inflammation, fibrous plaque formation, plaque rupture, and thrombosis (James and Brian, 2001). 
A low level of ascorbic acid is a major risk factor and indicator of atherosclerotic CVD, including 
hypertension and elevated concentrations of LDL, acute phase proteins, and hemostatic factors 
(Sagar et al., 2012). Increased platelet action in the body can increase the atherosclerosis risk and 
plaque calcification also increases the risk of atherosclerosis (Amala et al., 2012). Leptin may 
contribute to the development of classic risk factors of atherosclerosis such as arterial 
hypertension and diabetes mellitus (Jerzy, 2006)  
As we are living in a modern and technological world we have no time to get good sleep and 
we are in a hurry and get pressure at work so that we get stress and depression because that we 
may also have a chance of getting atherosclerosis. We may prevent it by doing yoga, listening 
to music, and gardening.  
2. Molecular and Cellular of Atherosclerosis  
Atherosclerotic vascular disease is the cause of Myocardial-infarction, stroke and ischemic heart 
pain, and sudden cardiac death. These diseases are the leading causes of death in the world, as 
a result, it also causes obesity and type 2 Diabetes which are potent risk factors of atherosclerosis. 
This disease is initiated by subendothelial retention of apolipoprotein B (apoB) –containing 
lipoproteins in the focal areas of arteries. (Ira Tabas et al-2015). About 462 genes have been 
manipulated by molecular methods to study their effects on the initiation, promotion, and 
progression of atherosclerosis. There are signaling pathways that are highly relevant to 
atherogenesis, these pathways include Insulin receptors; Ras and MAPK activation; above 75% of 
alternate transcriptional start sites, and alternate splice sites are found in human genes, they 
provide isoforms with the flexibility of expression. From cancer literature, they adapted four major 
steps that manifest atherosclerosis. The steps are 1) initiation of endothelial activation and 
inflammation; 2) promotion of intimal lipoprotein deposition; 3) progression of complex plaques 
by plaque growth, fibrosis, thrombosis, and enlargement of necrotic core,4) precipitation of acute 
events like myocardial infarction, sudden coronary death. 
The chemical, mechanical or immunological insult or injury or activation of endothelium leads to 
endothelium dysfunction which initiates the atherosclerosis process. Endothelium dysfunction also 
triggers the inflammatory response. Macrophages, monocytes, vascular smooth muscle cells, T- 
lymphocytes are involved in the inflammatory response. 
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The progression and complication of molecular determinants of atherosclerosis are numerous. 
Elevated plasma lipids and glucose are the major molecular risk factors of atherosclerosis and 
cardiovascular disease. Hypertension, smoking, and aging are non-molecular risk factors but 
when they undergo molecular action of intermediates of inflammation oxygen balance they may 
be a major contribution of atherosclerosis. 
Retention of lipoprotein is the key initiation of atherosclerosis and increases the level of plasma 
lipids particularly low density and very-low-density lipoprotein induces dysfunction of the 
endothelium.  In atherosclerosis progression and complication, molecular factors like growth 
factors, chemokines, enzymes, and vasoactive substances, and apoptosis signals are involved. 
These molecular factors are involved both as a marker for atherosclerosis disease and play an 
important role in the pathogenesis of the disease. Inflammatory cells that present in 
atherosclerotic lesions at the development stage exhibit markers prominent in sites of plaque 
rupture. (E. Mannarino, et al-2008). The development of molecular pathways involved in lesion 
progression and the mechanism in atherosclerotic plaque are understandable for the last several 
decades.  
 
3. Role of RNA in atherosclerosis  
MicroRNAs (miRNAs) are defined as single-standard, non-coding RNA molecules that synthesize 
protein by interacting with messenger RNAs (mRNA). Micro RNA is also used for its role in tempering 
gene expression. The gene expression is suppressed by miRNA either by cleaving or degrading its 
target mRNA or inhibiting the translation process. In a report, they say that miRNA plays an 
important role in silencing target genes and also reduces the synthesis of protein and function of 
cells, therefore it has been substantiated that miRNA plays a vital role in endothelial injury, cell 
attachment, growth, and inflammatory responses. It also suggested that miRNA act as a regulator 
of smooth muscle proliferation and phenotypic changes and also influence macrophage activity. 
Thus by understanding this influence, Yao Lu et al said that miRNAs present on these cells drive 
the progression of atherosclerosis and its role in the process of vascular disease.  
                       
Figure2: Role of RNA in atherosclerosis 
(Yao Lu-2018) 
MiR -34a, miR217, and miR-146a are types of microRNA. MiR -34a influences proliferation and 
differentiation in endothelial cells, overexpression of miR34a in endothelial cells decreases Sirtuin-
1[SIRT-1] levels. Various studies say that an increased level of miR34a in atherosclerotic arteries is 
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MiR-22 was transcriptionally regulated by the action of TGF-β1, involving a p53-dependent 
mechanism. MicroRNAs responsible for regulating SMC differentiation- MiR-143 and MiR-145, are 
decreased in diseased vessels. This suggests that a reduction in the expression of these microRNAs 
shows the differentiation of SMCs that influence the formation of the lesion that is responsible for 
the progression of atherosclerosis. 
MiR-1 was observed to steadily increase in the differentiation process from embryonic stem cells 
to SMC. MiR-1 induces SMC differentiation by the repression of Klf and Pim-1 (a serine/threonine 
kinase) which serves as a negative regulator of SMC differentiation. When MiR-10a was increased, 
Retinoic acid induces SMC differentiation from embryonic stem cells. This increase results from a 
retinoic acid-induced nuclear translocation of NF- κB. MiR-10a binds to 3'-UTR of HDAC4 which is 
a negative regulator of SMC differentiation. MiR-21 In a report it says that when MiR-21 is involved 
in TGFβ- and BMP4-induced SMC differentiation by down-regulating programmed cell death 4 
(PDCD4), which is a repressor of SMC contractile genes. However, there was still evidence that 
MiR-21 is repressed by the increase. 
Non-coding RNAs play a key role in gene transcription, post-transcriptional processing, chromatin 
modification, and epigenetic changes. Especially lncRNAs play a vital role in the growing number 
of human systemic diseases such as cardiovascular, cancer, and immune diseases. The initiation, 
propagation, and development of atherosclerosis, obesity-associated systemic inflammation, 
and oxidative stress play an important role.  
4. Immunological aspects 
The immune response was transported by the induction of monocyte-derived cells into sub-
endothelial space, which differentiates into mononuclear phagocytes that process accumulated 
normal and modified lipoproteins, and change them into cholesterol-laden "foam cells". Foam 
cells are classified as a 1) type of macrophage, 2) persist in plaques, and 3) promoting disease 
progression. Macrophages are the most important immune cell in arterial plaques, have been 
evoked to play a vital role in immune responses and progression of atherosclerosis. Macrophages 
primarily initiate from circulating monocytes and resident tissues. They are employed to the lesion 
site by holding to activated endothelial cells (ECs) and move into the sub-endothelial cell space. 
Then, macrophage proliferation enhances the major replenishment mechanism in plaques. 
Macrophages are the essential cells in atherosclerosis, with the quantity and phenotype of cells 
in plaques inducing both disease progression and regression. (Kathryn Moore et al-2013).  
Studies have shown that increased lesion CD68+ macrophages are linked with a complex risk of 
CVD and stroke. Macrophages are heterogeneous and are categorized into pro-inflammatory 
and anti-inflammatory phenotypes, which are known as M1 and M2 phenotypes. (Sozzani S, et al-
2004). 
Atherosclerosis is a non-resolving inflammatory condition, in which monocytes continue to enter 
plaques and differentiate into macrophages as atherosclerotic lesions progress. Significantly, 
macrophages promote size-independent changes in plaque morphology, remarkably necrotic 
core formation, and fibrous cap thinning that describe vulnerable plaque. The methods of these 
processes in plaque progression are predominantly relevant to acute atherothrombotic 
cardiovascular disease in humans. (Virmani et al., 2002). 
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Figure 3 - The role of macrophages in advanced atherosclerosis 
(Moore KJ, Tabas. 2011) 
Although monocytes are active in the plaque during the growth, they have the potency to 
emigrate from the plaque, under some experimental conditions that are related to a decrease in 
plaque size and regression of atherosclerosis. Monocytes may enter lymphatic vessels and move 
to drain lymph nodes, or they may migrate across the arterial endothelium to the artery lumen 
and directly enter the circulating bloodstream. 
 
5. Drugs  
Cholesteryl ester transfer protein (CETP) is a lipid transfer protein that enables the transport of 
cholesterol ester and TG inside the lipoproteins in the blood to resolve the method of transfer of 
cholesterol ester from the HDL to the LDL and VLDL which have to be proatherogenic. Therefore 
the movement of cholesterol esters from HDL to LDL by CETP starts lowering HDL. Inhibition of CETP 
is a choice of treatment in the lipid profile associated with disorders like atherosclerosis and type 
II diabetes.  
 
 
5.1. Synthetic drugs  
In many classes, cardiovascular drugs have established anti-inflammatory properties in their 
targeted actions on altering the contributory risk factors such as hypertension and hyperlipidemia. 
Among the antihypertensive drugs, angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers have been shown to inhibit the inflammatory effects of angiotensin II within the 
modulation of pro-inflammatory cytokines, NF-kB, oxidative stress, and nitric oxide synthesis. Over 
50 000 000 people in the United States take aspirin for the prevention of coronary heart disease 
and due to clear benefits that exert on the risk of clinical outcomes by the reduction of platelet 
activation and aggregation mainly by inhibiting platelet COX-1.  
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5.2. Vaccines 
The effect of immunization with LDL was thought to result from the antibody-mediated elimination 
of oxidized LDL particles, but studies suggested that antigen-specific TREG is an essential anti-
inflammatory mechanism. An LDL vaccine against atherosclerosis is under development and 
expected to be evaluated in clinical trials in the future. 
(GK Hansson et al., 2015)  















Methotrexate  Folic acid 
antagonist  
↓ Atherosclerosis and 














Canakinumab  IL-1βneutralizing 
monoclonal antibody  











antibodies against the 
IL-12 subunit p40 
(common to IL-12 and  
IL-23)  
↑ Atherosclerosis after  
IL-12 administration to  
Apoe–/– mice   
↓ atherosclerosis in Apoe 
and Il12 double-
knockout mice  
↔  




 (↑-increase; ↓- decrease; ↔no change occurred; NA-non available) 
(G k Hansson et al., 2015) 
5.3. Natural drugs  
The medicinal properties of garlic (Allium sativum L.) are known for thousands of years. The 
valuable effects of garlic in the treatment of cardiovascular diseases (CVD) were tough to prove 
because of the mild effect, long frame, and complex pathogenesis of atherosclerosis and related 
CVD. Garlic-based preparations are supposed to have cardioprotective and anti-atherosclerotic 
effects, such as improving blood lipid profile, inhibiting cholesterol biosynthesis, suppressing low-
density lipoprotein (LDL) oxidation, modulating blood pressure, controlling platelet aggregation, 
lowering plasma fibrinogen level, and increasing fibrinolytic activity. These potential effects 
appear to be very promising to the extent of challenge for atherosclerosis on modern medicine 
and essential for novel and safe medications. Atherosclerosis is a multifactorial disease, which is 
not entirely dependent on conventional cardiovascular risk factors. Direct anti-atherosclerotic 
effects of garlic therapy in atherosclerosis should prevent the growth of prevailing atherosclerotic 
lesions and the formation of new ones. The most intriguing property of garlic-based preparations 
is direct anti-atherosclerotic activity, which is independent of the moderate reduction of 
cardiovascular risk factors associated with garlic. The components in garlic can control two 
important intracellular enzymes that are responsible for cholesterol intracellular metabolism. 
Allicor, a garlic-based preparation, prevented cholesterol accumulation in cultured cells when 
treated with serum from atherosclerosis patients after a single dose, this was shown to reduce 
serum atherogenic potential. Garlic ingredients are known to inhibit inflammation signaling, 
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including TNF, IL-1-beta, ICAM-1, and HLA-DR expression and secretion. Therefore, they have 
beneficial effects at the arterial wall cells level. (Sobenin et al., 2019) 
 
Figure 4 - Plausible effects of medicinal plants on different stages of atherosclerosis 
development 
(Tatiana V kirichenko et al., 2020) 
Use of pomegranate (Punica granatum L.), which has multiple anti-atherosclerotic activities. Thus, 
ellagic acid that is present in the pomegranate promotes cholesterol deletion by regulating the 
LXR/PPAR-ABCA1 pathway. Pomegranate peels up-regulate mRNA expression of LXRα and 
ABCA1. ROS levels produced by mitochondria are reduced by ellagic acid and punicalagin in 
pomegranate by an antioxidant effect. Moreover, pomegranate possesses an anti-inflammatory 
effect due to pomegranate peel, flower, and seed oil that may reduce plasma levels of IL-6 and 
TNFa, pomegranate flower increases the anti-inflammatory cytokine IL-10 and, in addition, 
pomegranate extract reduces the translocation of NF-κB from the cytosol to the nucleus. LPS-
induced pro-inflammatory cytokine activation is decreased by Pomegranate ellagic acid, peel 
polyphenols, and punicalagin.   
 
6. Spices 
Nutrition research recommended that the nutrients contained in vegetables and fruits offer a host 
of athero-protective effects. For example, the intake of fiber, a plant-based nutrient that is 
associated with reduced CVD risk. The types of spices consumed vary across cultures (table 3). In 
the Mediterranean diet, they use herbs and spices commonly in cooking because it increases the 
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flavor of food and reduces the need for salt and oil. Five-spice powder is a popular condiment in 
China, and it also includes peppercorns, fennel, cloves, star anise, and cinnamon, all of these 
spices are proven to improve CVD symptoms.  
Table 3- Types of spices consumed across cultures 
Diet category  Spices  Prevalence of CVD 
Western diet  Spice-free with salt and sugar 11-15% 
Mediterranean diet  Anise, Basil, Bay, Cardamom, 
Cinnamon, Chilies, Cloves, 
Cumin, Coriander, Fenugreek,  
Mint, Peppers, Saffron  
1.5-3.2% 
Chinese diet  Cardamom, Cumin, Cloves,  
Ginger, Nutmeg, Star anise  
5% 
Indian diet  Cardamom, Clove, Cassia, 
Pepper, Cumin, Coriander, 
Nutmeg, Mustard seed,  
7-11% 
Arabian diet  Saffron, Pepper, Allspice,  
Turmeric, Garlic, Parsley,  
Coriander   
7-13% 
(Pi-fen et al., 2018) 
Studies have shown that the Mediterranean diet (MedD) is associated with a reduction in a variety 
of inflammatory molecules implicated in atherosclerosis and CVD incidence and mortality as well 
as an improvement in endothelial functions. The diet’s chief component, extra virgin olive oil 
(EVOO), contains various bioactive phenolic compounds that possess anti-inflammatory and 
antioxidative properties. The use of EVOO as the prevention of frequent complications of CVD 
such as Heart failure and atrial fibrillation.  
 
7. Counseling for Atherosclerosis  
Changing risk factors outlines an aging population, the burden of disease is expected to increase. 
Peripheral arterial disease (PAD) is a global health issue associated with high levels of mortality 
and morbidity. The prevalence of asymptomatic PAD that is estimated is between 3% and 10% in 
the adult population. With altering risk factor profiles and aging demographics, this disease 
burden is expected to increase significantly during the next 20 years. There are local 
complications of PAD, such as intermittent claudication, loss of function, ulceration, and 
gangrene, and amputation. It is also an essential marker for systemic atherosclerosis which 
involves the coronary, cerebral, and renal vascular territories. Individuals with PAD have a two to 
six times greater risk of cardiovascular and cerebrovascular events compared with age-matched 
individuals in the general population. Only 20% to 30% of patients with PAD die of non-
cardiovascular causes.   
Therefore, medical and lifestyle management of PAD has to include therapies that improve 
functional consequences and reduce adverse cardiovascular and limb events. Evidence for 
these treatments and makes clinical recommendations accordingly. Exercise therapy and regular 
physical activity are positive predictive indicators for all-cause mortality in patients with PAD. 
Hence, exercise is the most effective non-invasive therapy to improve pain symptoms and 
ambulation in intermittent claudication. (Parvar. S et al., 2018) 
8. Medication Therapy and Secondary Prevention of CVD 
CVD may place individuals at risk for reduced quality of life, heart failure, and death, making 
secondary prevention crucial. The rate of progression of atherosclerosis is influenced by 
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cardiovascular risk factors: tobacco use, an unhealthy diet, and physical inactivity (result in 
obesity) elevated blood pressure (hypertension), abnormal blood lipids (dyslipidemia), and 
elevated blood glucose (diabetes). For the prevention of cardiovascular disease, it is divided into 
three steps- primary, secondary and tertiary prevention of arbitrary.  
The determination of applying the guidelines is to motivate and assist high-risk individuals to lower 
their cardiovascular risk by:  
• Stop use of tobacco, or reduce the amount smoked;  
• Prefer healthy food diet; 
• Reducing body mass index (to less than 25 kg/m2) and waist-hip ratio (to less than 0.8 
in women and 0.9 in men (these may be different for different ethnic groups); 
• Lowering blood pressure (to less than 140/90 mmHg);   
• Lowering blood cholesterol (to less than 5 mMol/l or 190 mg/dl);   
• Lowering LDL-cholesterol (to less than 3.0 mMol/l or 115 mg/dl);   
• Controlling glycemia, especially in those with impaired fasting glycemia and impaired 
glucose tolerance or diabetes;  
• Aspirin (75 mg daily), should be taken once the blood pressure has been controlled.  
• Decrease the energy intake and should maintain an appropriate body weight  
• Reduce the percentage of energy derived from fat, limit the number of SFAs with 
polyunsaturated fatty acids (PUFAs), and reduce the intake of trans fatty acids  
• Intake of omega-3 PUFAs should be increased 
 
9. Conclusion  
The atherosclerosis lesion shows highly specific cellular and molecular responses and the process 
of vascular injury causes cardiovascular risk and activation of inflammation lesions and apoptosis 
and the contribution of progenitor cells that repair molecular signals. Micro RNA, non-coding RNA 
plays an important role in atherosclerosis. The RNAs modulate the pathophysiology of 
atherosclerosis development. Receptors of microRNA proliferate and regulate endothelial 
activation and smooth cell Macrophages, monocytes, T-Cell, and natural killer cells are involved 
in the boosting of the immune system to prevent atherosclerosis lesion formation. The use of 
natural drugs prevents atherosclerosis without any side effects.    
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